Aligos Therapeutics is developing targeted small molecule therapies for liver and viral diseases, utilizing medicinal chemistry to create best-in-class oral agents like ALG-055009 for metabolic dysfunction-associated steatohepatitis and ALG-000184 for chronic hepatitis B. The company addresses the significant unmet medical needs for more effective treatments in these areas, aiming to improve patient outcomes.
Funding
$92M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Liver and viral diseases, such as metabolic dysfunction-associated steatohepatitis (MASH) and chronic hepatitis B (CHB), present significant unmet medical needs due to the limited efficacy of existing treatments. Current therapeutic options often fail to adequately address the underlying disease mechanisms, resulting in suboptimal patient outcomes.
Solution
Aligos Therapeutics develops targeted, oral small molecule therapies designed to improve treatment efficacy for liver and viral diseases. Their medicinal chemistry expertise enables the creation of best-in-class agents, such as a thyroid hormone receptor beta (THR-β) agonist for MASH and a capsid assembly modulator (CAM-E) for CHB. These purpose-built drugs are designed with enhanced pharmacologic properties to address the specific needs of patients with these conditions. The company's pipeline focuses on differentiated therapies with the potential to significantly impact patient health.
Target Audience
The primary target audience includes patients suffering from liver and viral diseases, specifically MASH and chronic hepatitis B, as well as healthcare providers specializing in hepatology and virology.
Features
- ALG-055009: A best-in-class oral small molecule thyroid hormone receptor beta (THR-β) agonist for MASH.
- ALG-000184: A best-in-class oral small molecule capsid assembly modulator (CAM-E) for chronic hepatitis B (CHB).
- Focus on developing oral agents for improved patient convenience and adherence.
- Medicinal chemistry driven approach to create highly targeted and effective therapies.